Fast Five Quiz: Thyroid Cancer Practice Essentials

Elwyn C. Cabebe, MD; Lori J. Wirth, MD


September 08, 2022

A study published in July 2020 found that patients with thyroid cancer who have undergone treatment such as surgery, with or without radioiodine, are not considered to be at higher risk for viral infection, including from SARS-CoV-2.

Guidance from the Thyroid Cancer Forum UK, the Society for Endocrinology, and the British Thyroid Association states that patients on suppressive doses of thyroxine should continue their current dose. Suppressive doses of levothyroxine do not increase the risk for COVID-19 infection. However, patients who are receiving multikinase inhibitors or chemotherapy are at an increased risk for severe COVID-19 and should take extra precautions.

Learn more about COVID-19.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.